Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

We read with great interest the study by Passaro et al. reporting an improved progression-free survival with amivantamab and amivantamab plus lazertinib in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) after disease progression on osimertinib.1 Despite highly promising efficacy data, important cardiovascular safety signals were observed in the study, which require specific consideration. In detail, the risk of venous thromboembolism (VTE) in patients treated in the amivantamab–lazertinib–chemotherapy arm was 22%, compared with 10% in the amivantamab–chemotherapy arm and 5% in patients treated with chemotherapy only.